<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Celon Pharma Sa — News on 6ix</title>
    <link>https://6ix.com/company/celon-pharma-sa</link>
    <description>Latest news and press releases for Celon Pharma Sa on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 08 Oct 2025 10:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/celon-pharma-sa" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836343a78dffbe2df1498f5.webp</url>
      <title>Celon Pharma Sa</title>
      <link>https://6ix.com/company/celon-pharma-sa</link>
    </image>
    <item>
      <title>FDA Clears Celon Pharma’s Schizophrenia Drug for Phase 3 Trial</title>
      <link>https://6ix.com/company/celon-pharma-sa/news/fda-clears-celon-pharma-schizophrenia-100000575</link>
      <guid isPermaLink="true">https://6ix.com/company/celon-pharma-sa/news/fda-clears-celon-pharma-schizophrenia-100000575</guid>
      <pubDate>Wed, 08 Oct 2025 10:00:00 GMT</pubDate>
      <description>FDA clears path for Phase 3 testing following positive Type B meetingRegulatory alignment confirms preclinical data sufficient for pivotal initiationPhase 3 to include two 28-day trials and a 12-month safety extensionCPL’36 demonstrated strong efficacy and safety in prior Phase 2 studyProgram expansion planned into additional CNS indications, including Parkinson’s disease WARSAW, Poland, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Celon Pharma S.A. (WSE: CLN) announced today it has secured a key regulator</description>
    </item>
  </channel>
</rss>